Advertisement
ADVANCED SEARCH

This Article Figures Only Full Text Full Text (PDF) Submit a response View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thompson, I. M. Articles by Ankerst, D. P. Search for Related Content PubMed PubMed Citation Articles by Thompson, I. M. Articles by Ankerst, D. P. Related Collections Screening tests Prostate Cancer Related Articles

Prostate-specific antigen in the early detection of prostate cancer

From the Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Tex.

Correspondence to: Dr. Ian Thompson, Department of Urology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio TX 78229; fax 210 567-6868; thompsoni{at}uthscsa.edu

Abstract

Throughout Canada, the United States and much of Europe, prostate-specific antigen (PSA) screening for prostate cancer has proliferated over the past 2 decades, leading to dramatic increases in detection rates of prostate cancer. Although it has unquestionably led to increased detection of cancer and a migration to lower-stage and -volume tumours, it is still unknown whether PSA screening significantly reduces mortality from prostate cancer. Often thought to be dichotomous (i.e., either normal or elevated), PSA measurements actually reflect cancer risk, with the risks of cancer and of aggressive cancer increasing with the level of PSA. The recently developed risk calculator from the Prostate Cancer Prevention Trial, which integrates family history of prostate cancer, digital rectal examination findings, PSA test result, age, ethnicity, and history of a prior prostate biopsy with a negative result, allows clinicians to assess a patient's individual risk of cancer. This risk should be examined in the context of a patient's life expectancy and comorbidity as well as his concern about the possibility of prostate cancer. The terms "normal" and "elevated" as descriptors of PSA results should be abandoned.

This article has been cited by other articles:

				A. Maxwell, C. R. McCudden, F. Wians, and M. S. Willis Recent Advances in the Detection of Prostate Cancer Using Epigenetic Markers in Commonly Collected Laboratory Samples Lab Med, March 1, 2009; 40(3): 171 - 178. [Abstract] [Full Text] [PDF]

				G. Castellano, G. Malaponte, M. C. Mazzarino, M. Figini, F. Marchese, P. Gangemi, S. Travali, F. Stivala, S. Canevari, and M. Libra Activation of the Osteopontin/Matrix Metalloproteinase-9 Pathway Correlates with Prostate Cancer Progression Clin. Cancer Res., November 15, 2008; 14(22): 7470 - 7480. [Abstract] [Full Text] [PDF]

				H. Li, L. L. Xu, K. Masuda, E. Raymundo, D. G. McLeod, A. Dobi, and S. Srivastava A Feedback Loop between the Androgen Receptor and a NEDD4-binding Protein, PMEPA1, in Prostate Cancer Cells J. Biol. Chem., October 24, 2008; 283(43): 28988 - 28995. [Abstract] [Full Text] [PDF]

				M. Mimeault, P. P. Mehta, R. Hauke, and S. K. Batra Functions of Normal and Malignant Prostatic Stem/Progenitor Cells in Tissue Regeneration and Cancer Progression and Novel Targeting Therapies Endocr. Rev., April 1, 2008; 29(2): 234 - 252. [Abstract] [Full Text] [PDF]

eLetters:

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-2007, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.